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Background/Objectives. Embolization of the left gastric artery (LGA), which preferentially supplies the gastric fundus, has
been shown to produce weight loss in animal models. However, weight loss after LGA embolization in humans has not been
previously established. The aim of this study was to evaluate postprocedural weight loss in patients following LGA embolization.
Subjects/Methods. A retrospective analysis of the medical records of patients who underwent LGA embolization for upper
gastrointestinal(GI)bleedingwasperformed.Postproceduralweightlossinthisgroupwascomparedtoacontrolgroupofpatients
whohadundergoneembolizationofotherarteriesforupperGIbleeding.Results.Theexperimentalgroup(𝑁=1 9 ) lost an average
of7.3%oftheirinitialbodyweightwithinthreemonthsofLGAembolization,whichwassignificantlygreaterthanthe2%weightloss
observedinthecontrolgroup(𝑁=2 8 )(𝑃 = 0.006).Nosignificantdifferenceswereseenbetweenthegroupsinpreproceduralbody
mass index (BMI), age, postprocedural care in the intensive care unit, history of malignancy, serum creatinine, or left ventricular
ejection fraction. Conclusions. The current data suggest that body weight in humans may be modulated via LGA embolization.
Continued research is warranted with prospective studies to further investigate this phenomenon.
1. Introduction
The incidence of overweight and obese individuals in the
United States has dramatically increased over the last twenty
years and now includes nearly two-thirds of adults [1]. This
results in significant morbidity and mortality often related to
heart disease, stroke, type II diabetes, and even some cancers
[1].Thecurrenttherapeuticalternativesfortheoverweightor
obese patient include lifestyle modifications, a limited num-
ber of medical therapies, and bariatric surgery. However, the
growing obesity epidemic would suggest that these methods
aloneareinsufficient.Furthermore,invasivebariatricsurgery
c a r r i e sah o s to fp o t e n t i a lc o m p l i c a t i o n sf o rt h ep a t i e n t[ 2].
Recently, studies performed in animal models have demon-
strated that body weight can be modulated via percutaneous,
catheter-directed,transarterialembolizationoftheleftgastric
artery (LGA), the artery that preferentially provides blood
flow to the fundus of the stomach [3–6], although this effect
has not been established in humans. To further explore the
possibility that a catheter-directed approach may provide
a minimally invasive therapeutic alternative for obesity, we
performed a single-center retrospective review of patients
whounderwentLGAembolizationtodeterminewhetherthis
i n t e rv e n t i o nl e dt ow e i g h tl o s s .
2. Materials and Methods
This study was approved by our institutional review board
(IRB) and is HIPAA-compliant. Given the retrospective
nature of the evaluation, the requirement for obtaining info-
rmed consent was waived.
Hospital records were reviewed to identify all adult
patients who underwent catheter-directed embolization of
any branch of the celiac trunk for upper gastrointestinal
(GI) bleeding from 2000 to 2012. Patients were required to
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have three separate weights recorded in the electronic med-
ical record (EMR) which consisted of (1) preembolization
body weight recorded within the four weeks prior to the
procedure, (2) an early postembolization weight recorded
within the first 3 months after the procedure, and (3) a
delayed postembolization weight recorded at least 3 months
after the procedure. The first recorded weight in the EMR
within 3 months of the embolization procedure served as the
early postembolization weight. Any change in subject weight
recorded at this early time point is referred to as “immediate
change.” The first weight in the EMR to be recorded at
least 3 months after the embolization procedure served as
the delayed postembolization weight. Changes in subject
weight at this delayed time point are referred to as “delayed
change.” Patients who underwent embolization of the LGA
comprised the experimental group while patients who had
an embolization of any other artery of the celiac trunk
comprised the control group. Pertinent data were collected
from the EMR with a focus on potential confounding factors
f o rw e i g h tl o s ss u c ha sh i s t o r yo fm a l i g n a n c y ,c h e m o t h e r a p y
during the study period, participation in any weight-loss
programs during the study period, postprocedural intensive
care unit (ICU), left ventricular ejection fraction (LVEF) as
an indicator of congestive heart failure (CHF), and serum
creatinine as a marker of chronic kidney disease (CKD). The
body mass index (BMI) of each patient was also recorded
at each time point. Changes in weight were expressed as
a percentage of the original preembolization weight at the
early time point (immediate change) and delayed time point
(delayed change).
2.1. Statistical Analysis. Data were analyzed using GraphPad
Prism5.2(LaJolla,CA)softwareutilizingStudent’s𝑡-testwith
a 𝑃 value < 0.05 considered to be as significant.
3. Results
3.1. Patient Selection. By using the search term “left gas-
tric artery embolization,” the database retrieved 1213 adult
patients from 2000 to 2012. 797 of these patients had
undergone a catheter-directed arterial embolization of a
celiac trunk branch. Of these 797 patients, 40 patients had
LGA embolization and 757 patients had another branch of
t h ec e l i a ct r u n ke m b o l i z e d .5 9 9p a t i e n t s( 1p a t i e n tf r o m
the experimental group and 598 patients from the control
group)wereexcludedfromanalysisbecausetheembolization
procedure was performed for reasons other than upper GI
bleeding. An additional 151 patients (20 patients from the
experimental group and 131 patients from the control group)
were excluded from analysis because they did not have the
three requisite body weights documented in the EMR. Thus,
19patientswereeligibleforanalysisintheexperimentalgroup
while 28 patients were eligible from the control group.
3.2. Patient Characteristics. The experimental group com-
prised 12 males and 7 females with a mean age of 64.6 years
(range: 46–92) and a mean BMI of 30.3 (range: 20.3–58.9).
The control group comprised 15 males and 13 females with
a mean age of 58.7 years (range: 22–82) and a mean BMI of
Table 1: Number and types of malignancies in each patient group.
Experimental group (𝑁 = 11/19)C o n t r o l g r o u p ( 𝑁 = 14/28)
Colorectal (𝑁=3 )C o l o r e c t a l ( 𝑁=2 )
Lung (𝑁=1 )P a n c r e a t i c ( 𝑁=3 )
Laryngeal (𝑁=1 )L a r y n g e a l ( 𝑁=1 )
Renal (𝑁=1 )R e n a l ( 𝑁=1 )
Prostate (𝑁=2 )P r o s t a t e ( 𝑁=1 )
Gastric (𝑁=2 )L y m p h o m a ( 𝑁=2 )
Mesothelioma (𝑁=1 ) Neuroendocrine (𝑁=1 )
Ovarian (𝑁=1 )
Endometrial (𝑁=1 )
Melanoma (𝑁=1 )
29.2 (range: 18.1–50.3). No difference in the mean age (𝑃=
0.20)o rp r e p r o c e d u r a lB M I( 𝑃 = 0.70)w a ss e e nb e t w e e n
the groups. 58% of the experimental group had a history
of malignancy and four of these patients were receiving
chemotherapy during the study period. 50% of the control
group had a history of malignancy and six of these patients
were receiving chemotherapy during the study period. The
types of malignancies in the experimental group and in the
control group are shown in Table 1.Th e r ew a sn os i g n i fi c a n t
difference in the proportion of patients with a history of
malignancy(𝑃 = 0.29)orreceivingchemotherapyduringthe
study period (𝑃 = 0.97) between the two groups. Patients in
the experimental group spent an average of 5.3 days (range:
2–8 days; median: 6 days) in the ICU after embolization,
had a mean LVEF of 62% (range: 29–77%; median: 69%),
and had a mean serum creatinine of 0.8mg/dL (range: 0.5–
1.7; median: 0.75). Patients in the control group spent an
a v e r a g eo f1 3 . 1d a y s( r a n g e :3 – 4 5d a y s ;m e d i a n :6d a y s )i nt h e
ICU after embolization, had a mean LVEF of 68% (range:
56–75%; median: 69%), and had a mean serum creatinine
of 0.9mg/dL (range: 0.6–2.3; median: 0.8). No significant
differences between the two groups were found in the ICU
postprocedural care (𝑃 = 0.34), mean LVEF (𝑃 = 0.25),
or mean serum creatinine (𝑃 = 0.48). No patients in either
group participated in a formal weight-loss program during
the study period.
The causes of upper GI bleeding in the experimental
group and in the control group are shown in Table 2.Th e
arteriesembolizedinthecontrolgroupincludedsplenic(𝑁=
13), gastroduodenal (𝑁=7 ), right hepatic (𝑁=4 ), and left
hepatic(𝑁=4 )arteries.Themethodofarterialembolization
in the experimental group included coils (𝑁=9 ), gelfoam
(𝑁=5 ), and polyvinyl alcohol (PVA) particles (𝑁=5 ). The
methodofarterialembolizationinthecontrolgroupincluded
coils (𝑁=2 3 ), gelfoam (𝑁=3 ), and PVA particles (𝑁=2 ).
PVA particles ranging from 300 to 500𝜇m, 500 to 710𝜇m,
and710to1000𝜇mwereused,basedonoperatorpreferences.
3.3. Patient Weights. The early postembolization weights
were recorded at a mean of 1.6 months (range: 1–2.9, median:
1.3) in the experimental group and 1.5 months (range: 0.1–
2.9, median: 1.6) in the control group (𝑃 = 0.70). The
delayed postembolization weights were recorded at a meanJournal of Obesity 3
(a) (b)
Figure 1: 72-year-old male was found to have bleeding at the gastric fundus on endoscopy. (a) Digital subtraction angiography (DSA) of
the LGA (black arrow) demonstrated no evidence of contrast extravasation to suggest bleeding. A nasogastric tube is also seen (double black
arrows).(b)DSAperformedaftergelfoamembolizationoftheLGArevealedasignificantdecreaseintheopacificationofthearterialbranches
in the fundus (black arrow).
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Figure 2: Bar graph comparing the change in weight between
patients after LGA embolization (black bars) or embolization of
another celiac trunk branch (gray bars). Patients lost significantly
more weight after LGA embolization at the early time point
(𝑃 = 0.006) but the difference in weight loss was not statistically
significant at the delayed time point (𝑃 = 0.183).
of 13.6 months (range: 3–102.3 months, median: 10.4) in the
experimental group and 4 months (range: 3–22.4 months,
median: 4.5) in the control group (𝑃 = 0.007). Patients
who underwent LGA embolization lost, on average, 7.3%
of their body weight at the early time points (immediate
change) (range: −1% to 17.9%, SEM: 1.4) (Figures 1 and 2).
This was significantly greater than the 2% weight loss (range:
−18.3%to13.6%,SEM:1.1)observedinthecontrolgroupover
t h es a m ep e r i o d( 𝑃 = 0.006). At the delayed time points,
patients had lost an average of 3.5% of their preembolization
bodyweightafterLGAembolization(range:−21.1%to24.3%,
Table 2: Causes for upper GI bleeding.
Experimental group (𝑁=1 9 )C o n t r o l g r o u p ( 𝑁=2 8 )
Gastric ulcers (𝑁=8 ) Duodenal ulcers (𝑁=7 )
Nasogastric or gastrostomy
tube placement (𝑁=3 )
Splenic artery
pseudoaneurysm (𝑁=7 )
Gastric varices (𝑁=3 ) Surgical complication (𝑁=4 )
Gastric cancer (𝑁=2 ) Percutaneous complication
∗
(𝑁=3 )
Metastasis to the stomach
(𝑁=1 ) Pancreatitis (𝑁=2 )
Pancreatitis (𝑁=1 ) Hepatic artery
pseudoaneurysm (𝑁=2 )
Hematemesis in setting of
anticoagulation (𝑁=1 ) Pancreatic cancer (𝑁=1 )
Trauma (𝑁=1 )
Liver metastasis (𝑁=1 )
∗Indicates complications arising from either percutaneous biopsy or percu-
taneous abscess drainage.
SEM: 1.4). Patients in the control group had lost only an
average of 0.3% of their preembolization body weight at the
delayed time points (range: −1 7 %t o1 1 . 5 % ,S E M :1 . 4 ) ,w h i c h
was not statistically different from the experimental group
(𝑃 = 0.18). Weight loss was similar for patients with a
preprocedural BMI in the “obese” range (≥30) compared to
patients with a BMI of <30 for both groups at both time
points. Weight loss was also similar for patients who received
chemotherapy during the study period in comparison to
those who received no chemotherapy for both groups at both
time points. When comparing weight loss in patients who
underwent embolization using permanent embolic materials
(for example, coils or PVA particles) compared to emboliza-
tion using the nonpermanent gelfoam material, there was no4 Journal of Obesity
significant difference in weight loss for either group at either
time point.
4. Conclusions
Arepally et al. were the first to suggest a percutaneous,
catheter-basedapproachtotreatobesity[3].Theirhypothesis
was that selective LGA embolization could cause relative
ischemiainthemucosaofthegastricfundus,whichcould,in
turn,suppresstheproductionofthehormoneghrelin.Studies
haveshownthatghrelin,whichisprimarilysecretedfromthe
mucosaofthegastricfundus,hasapowerfulorexigeniceffect,
stimulating food intake and weight gain in both animal and
human models [7–9]. Thus, there is the possibility that an
intervention that acts to lower circulating ghrelin levels has
potential to treat obesity. Indeed, multiple preclinical studies
have been able to demonstrate suppressed serum ghrelin
levels and weight modification after LGA embolization using
both sodium morrhuate and clinically available beads as
embolic agents [3–6]. In humans, however, weight loss after
LGAembolizationhasnotbeenreported;sinceceliacangiog-
raphy and embolization of arterial branches arising from the
celiac trunk is a routine practice in interventional radiology,
we analyzed patients that had undergone LGA embolization
todeterminewhetherthisinterventionledtoweightloss.Our
data shows that patients undergoing LGA embolization to
stop a bleeding vessel lost more weight within three months
of embolization than a control group (𝑃 = 0.006)a l t h o u g h
there was no significant difference in the degree of weight
loss between the two groups at the delayed time point (𝑃=
0.18)( Figure 2). Of note, the “delayed change” weights of the
experimental group were recorded in the EMR at a much
latertimepoint(mean:13.6months)thanthoseofthecontrol
group (mean: 4 months) (𝑃 = 0.007). Prospective studies
involving a more rigorous weight measurement design may
reveal the degree of weight change potentially missed in this
retrospective study between 4 months and 13.6 months.
The weight loss in our study was modest and less sus-
tained when compared to that seen in bariatric surgery [10]
which may be due to recanalization of the embolized LGA,
the development of collateral flow to the fundus reestab-
lishing ghrelin production, and/or compensatory ghrelin
production from other sites in the body. Further, the goal
of care in the groups of patients evaluated in this study
was to stop a bleeding vessel and not to achieve weight
loss. Therefore, it is hoped that future refinements of the
procedure, including the use of liquid embolic agents, will
be able to achieve greater and more sustained weight loss.
Moreover, if effective, transarterial embolization of the LGA
would undoubtedly provide obese patients with a much less
morbid therapeutic option [2, 6].
Our study is limited by several factors. First, the analysis
was retrospective in nature and thus we were unable to
correlate our findings with patients’ serum ghrelin levels or
assess the efficacy of LGA in an exclusively obese patient
population. Even though we attempted to provide matched
controls, it would be impossible to control for the many
other potentially confounding variables involved in weight
loss. Second, the study was limited by a small sample size
which was due, in large part, to the fact that 599 patients
were excluded from analysis as their embolizations were
performed for reasons other than upper GI bleeding. These
excluded embolizations were most commonly done for the
treatmentofcancerviaeitherchemoembolizationorselective
internal radiation therapy (SIRT). An additional 151 patients
were excluded from analysis because they did not have the
requisite weights recorded in the EMR. In spite of these
limitations, the data suggest that transarterial embolization
of the LGA has the potential to become a therapeutic option
forthebariatricpatient.Randomized,prospectivestudiesare
certainlyneededtoconfirmitssafety,efficacyinhumans,and
role in relation to bariatric surgery.
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